Quick Answer
Humacyte, Inc. reported Operating Income of -$108.14 million for fiscal year 2025.
Humacyte, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$108.14M | +5.5% |
| 2024 | -$114.40M | -14.3% |
| 2023 | -$100.05M | -18.3% |
| 2022 | -$84.58M | -4.1% |
| 2021 | -$81.21M | -25.7% |
| 2020 | -$64.60M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$24.39M | +19.3% | +18.0% |
| June 30, 2025 | -$29.73M | -0.8% | -28.2% |
| March 31, 2025 | -$23.18M | +12.8% | +23.3% |
| September 30, 2024 | -$30.23M | -22.8% | -2.5% |
| June 30, 2024 | -$29.50M | -10.4% | -11.0% |
| March 31, 2024 | -$26.58M | -18.1% | -7.9% |
| September 30, 2023 | -$24.62M | -4.8% | +7.9% |
| June 30, 2023 | -$26.73M | -44.3% | -18.7% |
- Humacyte, Inc. showed an increase of +5.5% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Humacyte, Inc.’s operating income has declined by 67.4% (from -$64.60 million to -$108.14 million).
- The most recent figure is from Humacyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: